

Domingo Francisco Javier Dez Martnez

List of Publications by Year in Descending Order

Source:

<https://exaly.com/author-pdf/4030711/domingo-francisco-javier-diez-martinez-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287
papers

14,739
citations

71
h-index

110
g-index

326
ext. papers

17,220
ext. citations

5.6
avg, IF

6.47
L-index

#	Paper	IF	Citations
287	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.. <i>CKJ: Clinical Kidney Journal</i> , 2022 , 15, 865-872	4.5	1
286	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	0.4	
285	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 754499	5.4	3
284	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
283	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , 2021 , 42, 684-696	9.5	23
282	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , 2021 , 9, 268-277	7.9	13
281	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 1875-1887	12.3	14
280	Bases para la creaci3n de las unidades cl3nicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. <i>REC: CardioClinics</i> , 2021 , 56, 284-284	0.2	3
279	Heart failure-related skeletal myopathy. Potential involvement of myokines. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 1008-1012	0.7	1
278	The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021 , 23, 933-944	12.3	8
277	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 3512-3520	3.7	1
276	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2021 , 41, 391-402	1.5	1
275	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. <i>Diabetes Care</i> , 2021 , 44, 224-230	14.6	6
274	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2021 , 18, 479-498	14.8	20
273	Miopat3a esquel3tica en la insuficiencia cardiaca. Implicaci3n potencial de las miocinas. <i>Revista Espanola De Cardiologia</i> , 2021 , 74, 1009-1009	1.5	
272	Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
271	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, e703-e713	3.1	1

270	Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. <i>JACC Basic To Translational Science</i> , 2021 , 6, 12-21	8.7	11
269	Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , 2021 , 11, e267	5.7	3
268	Hypertrophic cardiomyopathy in myosin-binding protein C () Icelandic founder mutation carriers. <i>Open Heart</i> , 2020 , 7, e001220	3	2
267	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
266	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. <i>Diabetologia</i> , 2020 , 63, 1043-1054	10.3	10
265	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. <i>Circulation</i> , 2020 , 141, 751-767	16.7	27
264	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 835-843	0.7	3
263	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2204-2218	15.1	18
262	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 248-254	1.5	4
261	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020 , 40, 223-236	1.5	6
260	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 248-254	0.7	3
259	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. <i>Nefrologia</i> , 2020 , 40, 223-236	0.4	2
258	Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 735-744	15.1	17
257	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. <i>Journal of Hypertension</i> , 2020 , 38, 2036-2042	1.9	4
256	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. <i>Clinical Research in Cardiology</i> , 2020 , 109, 22-33	6.1	11
255	Reprint of "The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking". <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020 , 1867, 118521	4.9	5
254	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. <i>Hypertension</i> , 2019 , 73, 820-828	8.5	27
253	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 272-285	12.3	99

252	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005897	7.6	33
251	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019 , 1866, 1421-1432	4.9	29
250	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 1231-1240	2.7	5
249	Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1398-1410	15.1	33
248	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1016-1025	15.1	35
247	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1795-1806	15.1	52
246	Fibrosis miocárdica: hacia una nueva aproximación. <i>Revista Colombiana De Cardiología</i> , 2019 , 26, 142-151	0.1	
245	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. <i>European Heart Journal</i> , 2019 , 40, 979-981	9.5	4
244	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. <i>Heart</i> , 2019 , 105, 307-314	5.1	18
243	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 2305-2318	2.1	10
242	Biomarkers of Cardiovascular Disease 2019 , 319-330		
241	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. <i>Scientific Reports</i> , 2019 , 9, 2956	4.9	8
240	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. <i>Hypertension</i> , 2019 , 73, 602-611	8.5	44
239	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. <i>Journal of the American Heart Association</i> , 2019 , 8, e010430	6	3
238	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. <i>American Journal of Hypertension</i> , 2019 , 32, 15-17	2.3	2
237	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1696-1706	15.1	204
236	Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 860-871	15.1	152
235	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. <i>European Heart Journal</i> , 2018 , 39, 699-709	9.5	112

234	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. <i>Hypertension</i> , 2018 , 71, 280-288	8.5	90
233	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1290-1299	12.3	42
232	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018 , 39, 2793-2799	9.5	19
231	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. <i>Matrix Biology</i> , 2018 , 66, 110-124	11.4	25
230	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , 2018 , 5, 139-148	3.7	14
229	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , 2018 , 20, 460-470	12.3	16
228	Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. <i>FASEB Journal</i> , 2018 , 32, fj201701408R	0.9	24
227	Reply: Aortic Stenosis, Left Ventricular Remodeling, and Renin-Angiotensin System Blockade. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2984-2985	15.1	
226	Sex Dimorphism in the Myocardial Response to Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 962-973	8.4	51
225	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , 2018 , 72, 549-558	8.5	58
224	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 832-840	0.7	12
223	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. <i>Scientific Reports</i> , 2017 , 7, 41865	4.9	17
222	Myocardial fibrosis: biomedical research from bench to bedside. <i>European Journal of Heart Failure</i> , 2017 , 19, 177-191	12.3	195
221	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. <i>Scientific Reports</i> , 2017 , 7, 40696	4.9	30
220	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2017 , 113, 906-914	9.9	13
219	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. <i>Free Radical Research</i> , 2017 , 51, 389-396	4	16
218	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	27
217	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. <i>Journal of Hypertension</i> , 2017 , 35, 853-861	1.9	30

216	A Urinary Fragment of Mucin-1 Subunit Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , 2017 , 2, 811-820	4.1	16
215	Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 254-260	0.7	7
214	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥80 Years With Heart Failure and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2017 , 119, 2042-2048	3	16
213	Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 832-840	1.5	20
212	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. <i>JAMA Cardiology</i> , 2017 , 2, 995-1006	16.2	107
211	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. <i>Scientific Reports</i> , 2017 , 7, 16042	4.9	19
210	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. <i>Open Heart</i> , 2017 , 4, e000615	3	15
209	The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes. <i>Medical Clinics of North America</i> , 2017 , 101, 43-52	7	14
208	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. <i>European Journal of Heart Failure</i> , 2017 , 19, 167-176	12.3	62
207	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. <i>Clinical Science</i> , 2016 , 130, 2139-2149	6.5	8
206	Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 251-60	15.1	90
205	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 119-30	6.4	15
204	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , 2016 , 11, e0167582	3.7	19
203	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. <i>Journal of Hypertension</i> , 2016 , 34, 130-8	1.9	23
202	What is on the horizon for improved treatments for acutely decompensated heart failure?. <i>European Heart Journal Supplements</i> , 2016 , 18, G33-G42	1.5	
201	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. <i>Nature Communications</i> , 2016 , 7, 13710	17.4	118
200	Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	16
199	Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2449-56	15.1	132

198	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. <i>European Journal of Heart Failure</i> , 2015 , 17, 385-92	12.3	39
197	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. <i>International Journal of Cardiology</i> , 2015 , 185, 177-85	3.2	21
196	"Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 661-9	7.9	28
195	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. <i>European Journal of Heart Failure</i> , 2015 , 17, 764-71	12.3	73
194	Targeting β -secretases protect against angiotensin II-induced cardiac hypertrophy. <i>Journal of Hypertension</i> , 2015 , 33, 843-50; discussion 850	1.9	5
193	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	119
192	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. <i>JACC: Heart Failure</i> , 2015 , 3, 180-8	7.9	105
191	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. <i>Free Radical Biology and Medicine</i> , 2015 , 81, 1-12	7.8	20
190	Arterial hypertension in patients with heart failure. <i>Heart Failure Clinics</i> , 2014 , 10, 233-42	3.3	14
189	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. <i>Biomaterials</i> , 2014 , 35, 143-51	15.6	68
188	Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 2448-56	6.9	33
187	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231
186	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2014 , 48, 299-303	2	14
185	Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. <i>American Journal of Cardiovascular Drugs</i> , 2014 , 14, 275-85	4	24
184	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF- β up-regulation. <i>Clinical Science</i> , 2014 , 126, 497-506	6.5	74
183	Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?. <i>Hypertension</i> , 2014 , 63, 468-74	8.5	14
182	Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. <i>Hypertension</i> , 2014 , 63, 483-9	8.5	39
181	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2014 , 15, 463-9	1.9	22

180	Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014 , 28, 349-59	1.5	16
179	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2013 , 12, 143	8.7	24
178	T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. <i>Circulation: Cardiovascular Imaging</i> , 2013 , 6, 415-22	3.9	158
177	A synthetic peptide from transforming growth factor- β type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats. <i>Antioxidants and Redox Signaling</i> , 2013 , 19, 1607-18	8.4	14
176	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. <i>Journal of Hypertension</i> , 2013 , 31, 587-94	1.9	12
175	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. <i>Circulation: Heart Failure</i> , 2013 , 6, 1239-49	7.6	183
174	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. <i>Cardiovascular Research</i> , 2013 , 99, 111-20	9.9	83
173	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. <i>Clinical Science</i> , 2013 , 125, 291-300	6.5	10
172	Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. <i>Hypertension</i> , 2013 , 61, 120-9	8.5	35
171	Hypertensive heart disease 2013 , 152-166		1
170	Glucagon-like peptide 1 and cardiac cell survival. <i>Endocrinología Y Nutrición: Organo De La Sociedad Española De Endocrinología Y Nutrición</i> , 2012 , 59, 561-9		6
169	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. <i>Cardiovascular Ultrasound</i> , 2012 , 10, 10	2.4	58
168	Blockade of TGF- β signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2012 , 2012, 726940	6.7	14
167	GLP-1 and cardioprotection: from bench to bedside. <i>Cardiovascular Research</i> , 2012 , 94, 316-23	9.9	74
166	The influence of obesity on the assessment of carotid intima-media thickness. <i>Journal of Clinical Ultrasound</i> , 2012 , 40, 479-85	1	6
165	Cardiotrophin-1 in hypertensive heart disease. <i>Endocrine</i> , 2012 , 42, 9-17	4	20
164	Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. <i>Hypertension</i> , 2012 , 60, 563-73	8.5	52
163	Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. <i>Hypertension</i> , 2012 , 60, 677-83	8.5	118

162	Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. <i>Cardiovascular Research</i> , 2012 , 96, 81-9	9.9	19
161	New targets to treat the structural remodeling of the myocardium. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1833-43	15.1	129
160	Association of the peroxisome proliferator-activated receptor β gene L162V polymorphism with stage C heart failure. <i>Journal of Hypertension</i> , 2011 , 29, 876-83	1.9	6
159	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. <i>Journal of Hypertension</i> , 2011 , 29, 17-26	1.9	55
158	Towards the molecular diagnosis of hypertensive heart disease?. <i>Journal of Hypertension</i> , 2011 , 29, 660-2.9		1
157	Aspectos emergentes del sistema renina-angiotensina en la diabetes: ¿c3mo abordar su traslaci3n a la cl3nica?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011 , 11, 37-41	0.2	
156	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. <i>Proteomics - Clinical Applications</i> , 2011 , 5, 222-32	3.1	9
155	Angiotensin II and myocardial remodeling: do macrophages hold the key?. <i>American Journal of Hypertension</i> , 2011 , 24, 626-7	2.3	
154	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. <i>Cardiovascular Research</i> , 2011 , 92, 247-55	9.9	31
153	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2011 , 32, 177-83	9.5	16
152	Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H1361-72	5.2	65
151	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H2372-82	5.2	48
150	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. <i>Frontiers in Bioscience - Elite</i> , 2011 , 3, 1467-74	1.6	5
149	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H1-9	5.2	177
148	Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. <i>Hypertension</i> , 2010 , 55, 1418-24	8.5	89
147	A translational approach to hypertensive heart disease. <i>Hypertension</i> , 2010 , 55, 1-8	8.5	85
146	Association between left ventricular mass and telomere length in a population study. <i>American Journal of Epidemiology</i> , 2010 , 172, 440-50	3.8	46
145	G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. <i>Diabetes</i> , 2010 , 59, 2407-17	0.9	77

144	Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. <i>Cardiovascular Research</i> , 2010 , 87, 591-2	9.9	17
143	Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. <i>Cardiovascular Research</i> , 2010 , 88, 304-13	9.9	23
142	Circulating biomarkers of collagen metabolism in cardiac diseases. <i>Circulation</i> , 2010 , 121, 1645-54	16.7	168
141	Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. <i>New England Journal of Medicine</i> , 2010 , 363, 552-63	59.2	452
140	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010 , 78, 1275-80	9.9	31
139	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2010 , 28, 2219-26	1.9	5
138	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. <i>Journal of Hypertension</i> , 2010 , 28, 1944-50	1.9	32
137	Myocardial remodeling after infarction: the role of myofibroblasts. <i>Nature Reviews Cardiology</i> , 2010 , 7, 30-7	14.8	502
136	Corrigendum to Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension [FEBS Lett. 542 (2003) 27B1]. <i>FEBS Letters</i> , 2010 , 584, 4709-4709	3.8	
135	Vascular effects of cardiotrophin-1: a role in hypertension?. <i>Journal of Hypertension</i> , 2010 , 28, 1261-72	1.9	25
134	Do microRNAs regulate myocardial fibrosis?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009 , 6, 88-9		8
133	Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. <i>Hypertension</i> , 2009 , 54, 744-50	8.5	54
132	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. <i>Cardiovascular Research</i> , 2009 , 83, 586-94	9.9	40
131	Prevalence of left ventricular diastolic dysfunction in a general population. <i>Circulation: Heart Failure</i> , 2009 , 2, 105-12	7.6	233
130	Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. <i>Hypertension</i> , 2009 , 53, 236-42	8.5	120
129	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. <i>Free Radical Biology and Medicine</i> , 2009 , 46, 1058-67	7.8	33
128	TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 897-904	2.5	12
127	Towards a new paradigm about hypertensive heart disease. <i>Medical Clinics of North America</i> , 2009 , 93, 637-45	7	31

126	Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009 , 62, 305-13	0.7	2
125	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. <i>Journal of Hypertension</i> , 2009 , 27, 1420-30	1.9	12
124	Obesity-related cardiac and vascular structural alterations: beyond blood pressure overload. <i>Journal of Hypertension</i> , 2009 , 27, 1750-2	1.9	9
123	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. <i>Clinical Science</i> , 2009 , 116, 233-40	6.5	8
122	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. <i>Journal of Hypertension</i> , 2009 , 27, 418-24	1.9	39
121	A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. <i>Cardiovascular Research</i> , 2009 , 81, 601-9	9.9	75
120	Biochemical markers of myocardial remodelling in hypertensive heart disease. <i>Cardiovascular Research</i> , 2009 , 81, 509-18	9.9	57
119	Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition 2009 , 103-119		2
118	Renin-Angiotensin-Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease 2009 , 143-150		1
117	Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares (RECAVA). <i>Revista Espanola De Cardiologia</i> , 2008 , 61, 58-65	1.5	6
116	Cooperative Cardiovascular Disease Research Network (RECAVA). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008 , 61, 58-65	0.7	1
115	Vasodilator effect of ghrelin in the rat aorta. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2008 , 55, 448-53		4
114	Asociación de la metaloproteinasas-10 y el tabaquismo en sujetos sin enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2008 , 61, 1267-1273	1.5	6
113	Overexpression of human truncated peroxisome proliferator-activated receptor alpha induces apoptosis in HL-1 cardiomyocytes. <i>Cardiovascular Research</i> , 2008 , 79, 458-63	9.9	10
112	Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 2187-94	9.4	40
111	Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. <i>European Heart Journal</i> , 2008 , 29, 898-906	9.5	25
110	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 294, E52-60	6	60
109	AT1 receptor antagonism attenuates target organ effects of salt excess in SHR without affecting pressure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H853-8	5.2	75

108	Effects of aldosterone on the heart: beyond systemic hemodynamics?. <i>Hypertension</i> , 2008 , 52, 462-4	8.5	15
107	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. <i>Kidney International</i> , 2008 , S19-23	9.9	33
106	Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. <i>Endocrinology</i> , 2008 , 149, 4970-8	4.8	38
105	The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2319-27	5.6	30
104	Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease. <i>Circulation Journal</i> , 2008 , 72 Suppl A, A8-12	2.9	16
103	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. <i>Clinical Science</i> , 2008 , 114, 173-82	6.5	78
102	Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 859-67	15.1	93
101	Oxidative stress, endothelial dysfunction and cerebrovascular disease. <i>Cerebrovascular Diseases</i> , 2007 , 24 Suppl 1, 24-9	3.2	54
100	Hypertensive Heart Disease 2007 , 621-631		2
99	Avances en cardiopatía hipertensiva. Mecanismos de remodelado implicados en la transición de la hipertrofia a la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia Suplementos</i> , 2007 , 7, 14F-21F	0.2	
98	Arterial stiffness and extracellular matrix. <i>Advances in Cardiology</i> , 2007 , 44, 76-95		55
97	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. <i>Cardiovascular Research</i> , 2007 , 75, 536-45	9.9	28
96	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. <i>European Heart Journal</i> , 2007 , 28, 2785-91	9.5	27
95	Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. <i>Hypertension</i> , 2007 , 50, 977-83	8.5	40
94	Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 587-93	9.4	71
93	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. <i>Current Hypertension Reviews</i> , 2007 , 3, 1-7	2.3	5
92	Telomere dysfunction in hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 2185-92	1.9	46
91	A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1620-6	1.9	31

90	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. <i>Journal of Hypertension</i> , 2007 , 25, 2148-57	1.9	40
89	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). <i>Journal of Hypertension</i> , 2007 , 25, 1958-66	1.9	78
88	Mechanisms of cardiac fibrosis in hypertension. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 546-50	2.3	149
87	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. <i>Endocrinology</i> , 2007 , 148, 324-31	4.8	100
86	Oxidative stress and atherosclerosis in early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 2686-90	4.3	50
85	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. <i>Cardiovascular Research</i> , 2006 , 69, 899-907	9.9	38
84	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H1503-9	5.2	62
83	Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. <i>Diabetes</i> , 2006 , 55, 209-15	0.9	106
82	Highlight from International Congress. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 61-72.9		
81	C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1369-78	15.1	147
80	Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 89-96	15.1	184
79	A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2335-7	15.1	14
78	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. <i>Clinical Therapeutics</i> , 2006 , 28, 832-48	3.5	26
77	Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2006 , 41, 902-13	5.8	41
76	Angiotensin II and Myocardial Fibrosis, Clinical Implications 2006 , 193-213		
75	Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. <i>Journal of Hypertension</i> , 2006 , 24, 395-402	1.9	18
74	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2006 , 24, 1589-97	1.9	32
73	Apoptosis in hypertensive heart disease: a clinical approach. <i>Current Opinion in Cardiology</i> , 2006 , 21, 288-94	2.4	22

72	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. <i>Journal of Hypertension</i> , 2006 , 24, 1299-306	1.9	75
71	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System 2006 , 177-189		
70	Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. <i>Cytokine</i> , 2005 , 30, 282-92	4	42
69	Serum Markers of Fibrillar Collagen Metabolism in Cardiac Diseases 2005 , 101-113		
68	Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 209-16		116
67	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. <i>Journal of Hypertension</i> , 2005 , 23, 1445-51	1.9	58
66	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. <i>Journal of Hypertension</i> , 2005 , 23, 625-32	1.9	60
65	New directions in the assessment and treatment of hypertensive heart disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2005 , 14, 428-34	3.5	12
64	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. <i>Journal of Hypertension</i> , 2005 , 23, 2297-304	1.9	36
63	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. <i>Kidney International</i> , 2005 , S71-5	9.9	38
62	Oxidative stress and vascular remodelling. <i>Experimental Physiology</i> , 2005 , 90, 457-62	2.4	108
61	NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1452-7	9.4	58
60	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. <i>European Heart Journal</i> , 2005 , 26, 153-8	9.5	34
59	NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. <i>Antioxidants and Redox Signaling</i> , 2005 , 7, 1327-36	8.4	80
58	Profibrotic effects of angiotensin II in the heart: a matter of mediators. <i>Hypertension</i> , 2004 , 43, 1164-5	8.5	17
57	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004 , 42, 384-6	5.9	6
56	Surrogate markers for cardiovascular disease: structural markers. <i>Circulation</i> , 2004 , 109, IV22-30	16.7	146
55	Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. <i>Circulation</i> , 2004 , 110, 552-7	16.7	135

54	Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. <i>Hypertension</i> , 2004 , 44, 163-9	8.5	80
53	Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. <i>Circulation</i> , 2004 , 110, 1263-8	16.7	320
52	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. <i>Medical Clinics of North America</i> , 2004 , 88, 83-97	7	74
51	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2028-35	15.1	204
50	Peroxisome proliferator-activated receptor alpha and hypertensive heart disease. <i>Drugs</i> , 2004 , 64 Suppl 2, 9-18	12.1	18
49	Angiotensin II and the hypertensive heart: a role for the AT2 receptor?. <i>Journal of Hypertension</i> , 2004 , 22, 879-82	1.9	4
48	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 197-204	3.5	34
47	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. <i>Journal of Hypertension</i> , 2004 , 22, 2169-75	1.9	80
46	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. <i>Cardiovascular Research</i> , 2003 , 59, 549-62	9.9	81
45	Involvement of cardiomyocyte survival-apoptosis balance in hypertensive cardiac remodeling. <i>Expert Review of Cardiovascular Therapy</i> , 2003 , 1, 293-307	2.5	7
44	Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. <i>FEBS Letters</i> , 2003 , 542, 27-31	3.8	73
43	Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects. <i>Cerebrovascular Diseases</i> , 2003 , 16, 356-62	3.2	24
42	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. <i>Journal of Hypertension</i> , 2003 , 21, 2085-92	1.9	10
41	Corrigendum to "Furosemide in chronic heart failure: results of the TORIC study" [Eur. J. Heart Fail. 4 (2002) 507-13]. <i>European Journal of Heart Failure</i> , 2002 , 4, 667-667	12.3	0
40	Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. <i>European Journal of Clinical Investigation</i> , 2002 , 32, 291-4	4.6	11
39	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2002 , 16, 149-60	3.9	96
38	Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. <i>Hypertension</i> , 2002 , 39, 923-8	8.5	63
37	Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. <i>Endocrinology</i> , 2002 , 143, 3555-60	4.8	76

36	Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. <i>Circulation</i> , 2002 , 105, 2512-7	16.7	489
35	Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. <i>Hypertension</i> , 2002 , 39, 75-80	8.5	89
34	Ultrasonic backscatter and diastolic function in hypertensive patients. <i>Hypertension</i> , 2002 , 40, 239-43	8.5	24
33	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002 , 20, 1855-64	1.9	90
32	Torsemide in chronic heart failure: results of the TORIC study. <i>European Journal of Heart Failure</i> , 2002 , 4, 507-13	12.3	169
31	Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. <i>Journal of Molecular and Cellular Cardiology</i> , 2002 , 34, 1585-93	5.8	93
30	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <i>American Journal of Cardiology</i> , 2001 , 88, 1L-20L	3	164
29	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 1, 2-5	4.3	39
28	The loop diuretic torsemide interferes with endothelin-1 actions in the aorta of hypertensive rats. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 1, 18-21	4.3	40
27	Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. <i>Circulation</i> , 2001 , 104, 286-91	16.7	214
26	Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 1, 14-7	4.3	108
25	Biochemical assessment of myocardial fibrosis in hypertensive heart disease. <i>Hypertension</i> , 2001 , 38, 1222-6	8.5	143
24	Effects of antihypertensive agents on the left ventricle: clinical implications. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 263-79	4	18
23	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. <i>Journal of Hypertension</i> , 2001 , 19, 1871-6	1.9	60
22	Clinical aspects of hypertensive myocardial fibrosis. <i>Current Opinion in Cardiology</i> , 2001 , 16, 328-35	2.1	106
21	Vascular oxidant stress: molecular mechanisms and pathophysiological implications. <i>Journal of Physiology and Biochemistry</i> , 2000 , 56, 57-64	5	95
20	Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. <i>Hypertension</i> , 2000 , 36, 1065-71	8.5	49
19	Insulin-like growth factor I in essential hypertension. <i>Kidney International</i> , 1999 , 55, 744-59	9.9	22

18	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1999 , 17, 107-14	1.9	92
17	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. <i>Kidney International</i> , 1998 , 68, S10-3	9.9	3
16	Apoptosis in hypertensive heart disease. <i>Current Opinion in Cardiology</i> , 1998 , 13, 317-25	2.1	50
15	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. <i>Journal of Hypertension</i> , 1998 , 16, 863-70	1.9	12
14	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. <i>Journal of Hypertension</i> , 1997 , 15, 1159-65	1.9	11
13	Angiotensin converting enzyme inhibition corrects Na ⁺ /H ⁺ exchanger overactivity in essential hypertension. <i>American Journal of Hypertension</i> , 1997 , 10, 84-93	2.3	22
12	Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats. <i>American Journal of Hypertension</i> , 1997 , 10, 1147-52	2.3	12
11	Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. <i>American Journal of Hypertension</i> , 1995 , 8, 815-22	2.3	40
10	Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. <i>American Journal of Cardiology</i> , 1995 , 76, 14D-17D	3	12
9	Enhanced Na ⁽⁺⁾ -H ⁺ exchanger activity and NHE-1 mRNA expression in lymphocytes from patients with essential hypertension. <i>Hypertension</i> , 1995 , 25, 356-64	8.5	13
8	Treatment with lisinopril normalizes serum concentrations of procollagen type III amino-terminal peptide in patients with essential hypertension. <i>American Journal of Hypertension</i> , 1994 , 7, 52-8	2.3	35
7	Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. <i>Hepatology</i> , 1994 , 19, 1400-1406	11.2	142
6	Current work in the cell biology of left ventricular hypertrophy. <i>Current Opinion in Cardiology</i> , 1994 , 9, 512-9	2.1	2
5	Abnormal expression of anion exchanger genes in primary biliary cirrhosis. <i>Gastroenterology</i> , 1993 , 105, 572-8	13.3	118
4	Elevated levels of parathyroid hormone in essential hypertensive patients with increased erythrocyte potassium efflux. <i>American Journal of Hypertension</i> , 1991 , 4, 714-8	2.3	2
3	Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. <i>Gastroenterology</i> , 1991 , 101, 1354-60	13.3	11
2	Uremia and red blood cell sodium transport. <i>Nephron</i> , 1986 , 43, 155-7	3.3	8
1	Intracerebroventricular infusion of sodium chloride-rich artificial cerebrospinal fluid in rats induces natriuresis and releases an inhibitor of prostaglandin synthesis. <i>Clinical Science</i> , 1984 , 66, 621-4	6.5	9

